Videos

Approaching TKI (tyrosine kinase inhibitor)-based therapy for the first-line management of ALK+ mNSCLC.

Joshua M. Bauml, MD, presents the case of a 57-year-old man with ALK fusion+ non-small-cell lung cancer (NSCLC) and discusses recommended molecular tests to identify patients with molecular driver alterations.

Joshua M. Bauml, MD, provides insight on the treatment of ALK fusion+ non-small cell lung cancer with tyrosine kinase inhibitors.

Sara A. Hurvitz, MD, discusses sequencing the current therapies for patients with HER2-positive breast cancer.

An expert in ovarian cancer considers the future of ovarian cancer treatment, the use of PARP inhibitors and overcoming PARP resistance, and the emerging treatments options.

Erin Crane, MD, discusses the role of PARP inhibitors in the treatment of ovarian cancer.

Erin Crane, MD, provides an overview of the Phase 3 NOVA trial.

Erin Crane, MD, reviews second- and third-line treatment options and the impact of platinum sensitivity on treatment selection.

An expert in ovarian cancer discusses the role of molecular testing in ovarian cancer and the benefits of incorporating systemic frontline therapy into treatment plans.

Erin Crane, MD, provides an overview of a 63-year-old female patient diagnosed with recurrent ovarian cancer, discussing the initial presentation, clinical work-up, treatment, and her initial impression of the case.

Erin Crane, MD, reviews the case of a 63-year-old woman with recurrent ovarian cancer and discusses treatment options, the Phase 3 NOVA trial, and the future of ovarian cancer treatment.

An expert in multiple myeloma provides clinical pearls for disease management from initial diagnosis through multiple lines of therapy.

Dr. Natalie Callander describes promising new treatment approaches for patients with multiple myeloma.

An expert in multiple myeloma talks through the considerations for treatment selection in the third line for patient with multiple myeloma.

Dr. Natalie Callander provides insight on selection of second-line therapy after transplant patients with multiple myeloma.

Natalie Callander, MD, presents a case of a 68-year-old man with multiple myeloma and reviews first-line treatment options.

Natalie Callander, MD, presents a case of a 68-year-old man with multiple myeloma.

Adriana Rossi, MD, provides clinical pearls on the management of triple-class refractory multiple myeloma.

An expert in multiple myeloma shares her perspective on the significance of recent single-agent approvals for patients with triple-class refractory multiple myeloma and highlights promising combination regimens under investigation.

Dr Adrianna Rossi reviews considerations for treatment selection in the triple-class refractory setting in patients with multiple myeloma.

Adriana Rossi, MD, describes key clinical trials and their implications for the management of triple-class refractory multiple myeloma.

Dr Adriana Rossi reviews the therapeutic options for patients with triple-class refractory multiple myeloma in terms of mechanism of action and safety profile.

An expert in multiple myeloma provides insight on the treatment challenges for patients with triple-class refractory disease, particularly after fourth or later lines.

Adriana Rossi, MD, presents the case of a 75-year-old woman with triple-class refractory multiple myeloma.

Adriana Rossi, MD, describes the treatment approach in caring for a 75-year-old woman with triple-class refractory multiple myeloma [RRMM] while highlighting results from the relevant DREAMM and SOHO studies.

Vivek Subbiah, MD, explains what sets medullary thyroid cancer apart from other thyroid cancer histologies.

Oliver Sartor, MD, and Ulka Vaishampayan, MD, discuss noninvasive imaging with PSMA PET/CT for patients with advanced prostate cancer.

Oliver Sartor, MD, discusses the use of phenotypic biomarkers such as prostate-specific membrane antigen (PSMA), and how these biomarkers can be utilized for prediction of prognosis as well as responsiveness to therapy.

Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.

Danielle Hammond, MD, discusses prognostic factors indicating therapy success for patients with acute myeloid leukemia treated with a combination of venetoclax (Venclexta) and either decitabine or azacitadine.